SynthesisPloS one2021
Use of comorbidity indices in patients with any cancer, breast cancer, and human epidermal growth factor receptor-2-positive breast cancer: A systematic review.
Synthesis in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Lactate-to-albumin ratio as an independent predictor of short- and long-term mortality in ICU patients with malignant tumors: A retrospective cohort study.Oncology letters · 2026Article
- Quantification of Information Gained by Linking Claims Data to an Electronic Health Record Cohort of Patients With Metastatic Breast Cancer.Pharmacoepidemiology and drug safety · 2025Article
- Mortality risk stratification based on comorbidity status among cervical cancer patients in Lagos, Nigeria.International health · 2025Article
- Article
- Impact of major depressive disorder on breast cancer outcomes: a national retrospective cohort study.Journal of the National Cancer Institute · 2025Article
- Health-related quality of life in Thai patients with hepatocellular carcinoma and its influencing factors: A cross-sectional study.Belitung nursing journal · 2025Article
- Prognostic Factors Associated with Breast Cancer-Specific Survival from 1995 to 2022: A Systematic Review and Meta-Analysis of 1,386,663 Cases from 30 Countries.Diseases (Basel, Switzerland) · 2024Review
- Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.International journal of clinical oncology · 2024Article
- Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma.Drugs & aging · 2024Article
- Prospective Study of Incidence and Impact of Comorbidities on Breast Cancer Survival from India.Asian Pacific journal of cancer prevention : APJCP · 2023Observational
- Breast Cancer After Reduction Mammoplasty: A Population-Based Analysis of Incidence, Treatment and Screening Patterns.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2023Article
- Multi-morbidity and its association with common cancer diagnoses: a UK Biobank prospective study.BMC public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify comorbidity indices that have been validated in cancer populations, with a focus on breast cancer and human epidermal growth factor receptor-2-positive (HER2+) breast cancer. STUDY DESIGN AND
settingA systematic review of the literature on the use of comorbidity indices in any cancer, breast cancer, and HER2+ breast cancer using Ovid and PubMed.
resultsThe final data set comprised 252 articles (252 any cancer, 39 breast cancer, 7 HER2+ breast cancer). The most common cancers assessed were hematologic and breast, and the most common comorbidity index used was the Charlson Comorbidity Index (CCI) or a CCI derivative. Most validity testing of comorbidity indices used predictive validity based on survival outcomes. Hazard ratios for survival outcomes generally found that a higher comorbidity burden (measured by CCI) increased mortality risk in patients with breast cancer. All breast-cancer studies that validated comorbidity indices used CCI-based indices. Only one article validated a comorbidity index in HER2+ breast cancer.
conclusionCCI-based indices are the most appropriate indices to use in the general breast-cancer population. There is insufficient validation of any comorbidity index in HER2+ breast cancer to provide a recommendation, indicating a future need to validate these instruments in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.